<DOC>
	<DOCNO>NCT02097446</DOCNO>
	<brief_summary>- Indication : Benign tumor ovary ( mature teratoma , mucinous cystadenoma , serous cystadenoma ) - Intervention : Device ( Test group : Guardix-FL , Control group : Interceed ) - Primary Outcome Measure : Anti-adhesion Rate - Assessment : Operative Day ( Visit 2 ) , Post-Operative Day+7days ( Vist 3 ) , Post-Operative Day+4weeks ( Visit4 ) , Post-Operative Day+5weeks ( Visit 5 )</brief_summary>
	<brief_title>Safety Efficacy Antiadhesive Barrier GUARDIX-FL Women After Laparoscopic Cystectomy</brief_title>
	<detailed_description />
	<mesh_term>Genital Diseases , Female</mesh_term>
	<criteria>1 . The patient sign write informed consent 2 . Women age 18 44 3 . The patient able participate clinical trial period study 4 . The patient without abnormal figure screen laboratory examination 5 . The patient expect ovarian cystectomy benign ovarian tumor ( mature cystic teratoma , Mucinous cystadenoma , serous cystadenoma ) 1 . The patient take treatment medical product might barrier evaluate effectiveness 2 . The patient take medicine like antiadhesion , absorbable hemostat dose steroid , immunosuppressants 3 . The patient severe drug allergy 4 . The patient infectious disease abdominal pelvic cavity 5 . The patient previously participate another clinical trial within past 30 day 6 . The patient consider inappropriate study 7 . The pregnant 8 . The patient severe renal disease 9 . The patient severe systemic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>cystectomy</keyword>
</DOC>